Učitavanje...
Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase...
Spremljeno u:
| Izdano u: | J Kidney Cancer VHL |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Codon Publications
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6175852/ https://ncbi.nlm.nih.gov/pubmed/30319937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2018.109 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|